The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, driven by the increasing p ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Between the third and the fourth injection of Aflibercept, we do not normally see a change of vision or anatomy. Therefore, the plan is to exclude participants who had more than a 10 letter change ...

The study enrolled 52 subjects who were randomized 1:1 to receive either 10 μg UBX1325, or 2 mg of aflibercept control injections every eight weeks for six months after randomization. The primary ...